多発性骨髄腫 新規治療薬の使い方・考え方

出版社: 先端医学社
著者:
発行日: 2017-06-01
分野: 臨床医学:一般  >  薬物療法
ISBN: 9784865502695
電子書籍版: 2017-06-01 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

5,940 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,564 円(税込)

商品紹介

多発性骨髄腫治療における薬物療法の進歩は著しい。2015年以降だけでも革新的な新薬が5剤(POM、PAN、CFZ、ELO、IXB)も承認されている。今後、シークエンスを含めてどのように使いこなすのかが課題となるが、現時点でその情報は限られ不足している。本書ではこれらの薬剤の使い方・考え方、エビデンス解釈などを中心に、第一線でご活躍されるエキスパートより、解説・論考いただいた。

目次

  • 多発性骨髄腫 新規治療薬の使い方・考え方

    ―目次―

    Chapter 1 多発性骨髄腫に対する薬物療法 概論
     1.多発性骨髄腫における薬物療法の変遷を知る
     2.抗がん剤を中心とした薬物療法の基本的な考え方・進め方
     3.多発性骨髄腫の病態メカニズムと治療標的を整理する

    Chapter 2 各種治療薬の使い方・考え方
     各種治療薬の特徴・位置づけを知る(総論)
     1.ボルテゾミブ
     2.カルフィルゾミブ
     3.イキサゾミブ
     4.サリドマイド
     5.レナリドミド
     6.ポマリドミド
     7.パノビノスタット
     8.エロツズマブ
     9.ダラツムマブ

    Chapter 3 期待される次世代の治療
     1.免疫チェックポイント阻害薬
     2.CAR?T 療法
     3.その他 開発中の薬剤

    付 録 本書で取り上げたおもなレジメン

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Chapter 1 多発性骨髄腫に対する薬物療法概論

P.8 掲載の参考文献
2) Rajkumar SV, Dimopoulos MA, Palumbo A et al : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15 : e538-e548, 2014
3) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma : an overview of 6, 633 patients from 27 randomized trials. Myeloma Trialists'Collaborative Group. J Clin Oncol 16 : 3832-3842, 1998
4) Sonneveld P, Goldschmidt H, Rosifiol L et al : Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma : a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 31 : 3279-3287, 2013
5) Alexanian R, Barlogie B, Dixon D : High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 105 : 8-11, 1986
6) Alexanian R, Dimopoulos MA, Delasalle K et al : Primary dexamethasone treatment of multiple myeloma. Blood 80 : 887-890, 1992
7) Smith A, Wisloff F, Samson D et al, Nordic Myeloma Study Group, British Committee for Standards in Haematology : Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 132 : 410-451, 2006
8) Gay F, Oliva S, Petrucci MT et al : Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma : a randomised, multicentre, phase 3 trial. Lancet Oncol 16 : 1617-1629, 2015
9) Attal M, Lauwers-Cances V, Hulin G et al : Autologous transplantation for multiple myeloma in the era of new drugs : A phase III study of the Intergroup Francophone Du Myelome (IFM/DFCI 2009 Trial). Blood 126 : 391, 2015
10) 日本骨髄腫学会編 : 多発性骨髄腫の診療指針 第4版, 文光堂, 東京, 2016
11) NCCN Clinical Practice Guideline in Oncology. Multiple myeloma version 3. 2017. (https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf)
12) San Miguel JF, Schlag R, Khuageva NK et al : Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 31 : 448-455, 2013
13) Facon T, Dimopoulos M, Dispenzieri A et al : Final Analysis of Overall Survival from the First Trial. Blood 128 : 241, 2016
14) Durie BG, Hoering A, Abidi MH et al : Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777) : a randomised, open-label, phase 3 trial. Lancet 389 : 519-527, 2017
15) San Miguel J, Weisel K, Moreau P et al : Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003) : a randomised, open-label, phase 3 trial. Lancet Oncol 14 : 1055-1066, 2013
16) San-Miguel JF, Hungria VT, Yoon SS et al : Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma : a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 15 : 1195-1206, 2014
17) Lonial S, Dimopoulos M, Palumbo A et al : Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med 373 : 621-631, 2015
18) Stewart AK, Rajkumar SV, Dimopoulos MA et al : Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372 : 142-152, 2015
19) Moreau P, Masszi T, Grzasko N et al : Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 374 : 1621-1634, 2016
20) Dimopoulos MA, Oriol A, Nahi H et al : Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 375 : 1319-1331, 2016
21) Palumbo A, Chanan-Khan A, Weisel K et al : Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med 375 : 754-766, 2016
P.17 掲載の参考文献
1) Ozaki S, Handa H, Saitoh T et al : Trends of survival in patients with multiple myeloma in Japan : a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J 5 : e349, 2015
2) Rajkumar SV, Dimopoulos MA, Palumbo A et al : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15 : e538-e548, 2014
3) Cavo M, Rajkumar SV, Palumbo A et al : International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 117 : 6063-6073, 2011
4) Palumbo A, Rajkumar SV, San Miguel JF et al : International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 32 : 587-600, 2014
5) 多発性骨髄腫の診療指針 第4版, 日本骨髄腫学会編, 文光堂, 2016
6) Ludwig H, Durie BG, McCarthy P et al : IMWG consensus on maintenance therapy in multiple myeloma. Blood 119 : 3003-3015, 2012
7) Laubach J, Garderet L, Mahindra A et al : Management of relapsed multiple myeloma : recommendations of the International Myeloma Working Group. Leukemia 30 : 1005-1017, 2016
8) Giralt S, Garderet L, Durie B et al : American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant 21 : 2039-2051, 2015
9) Palumbo A, Avet-Loiseau H, Oliva S et al : Revised International Staging System for Multiple Myeloma : A Report From International Myeloma Working Group. J Clin Oncol 33 : 2863-2869, 2015
10) Quach H, Ritchie D, Stewart AK et al : Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 24 : 22-32, 2010
11) Sonneveld P, Avet-Loiseau H, Lonial S et al : Treatment of multiple myeloma with high-risk cytogenetics : a consensus of the International Myeloma Working Group. Blood 127 : 2955-2962, 2016
12) Kumar S, Giralt S, Stadtmauer EA et al : Mobilization in myeloma revisited : IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide, lenalidomide or bortezomib-containing regimens. Blood 114 : 1729-1735, 2009
13) Palumbo A, Rajkumar SV, Dimopoulos MA et al : Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22 : 414-423, 2008
14) Palumbo A, Bringhen S, Kumar SK et al : Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma : a meta-analysis of individual patient data. Lancet Oncol 15 : 333-342, 2014
15) Ozaki S, Tanaka O, Fujii S et al : Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. Int J Hematol 86 : 180-185, 2007
16) Dimopoulos MA, Sonneveld P, Leung N et al : International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol 34 : 1544-1557, 2016
17) Bringhen S, Larocca A, Rossi D et al : Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116 : 4745-4753, 2010
18) Moreau P, Pylypenko H, Grosicki S et al : Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma : a randomised, phase 3, non-inferiority study. Lancet Oncol 12 : 431-440, 2011
19) Atrash S, Tullos A, Panozzo S et al : Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J 5 : e272, 2015
20) Vickrey E, Allen S, Mehta J et al : Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 115 : 229-232, 2009
21) Moreau P, Masszi T, Grzasko N et al : Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374 : 1621-1634, 2016
22) San-Miguel JF, Hungria VT, Yoon SS et al : Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma : a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 15 : 1195-1206, 2014
23) Lonial S, Dimopoulos M, Palumbo A et al : Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373 : 621-631, 2015
24) Dimopoulos MA, Oriol A, Nahi H et al : Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375 : 1319-1331, 2016
25) Palumbo A, Chanan-Khan A, Weisel K et al : Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375 : 754-766, 2016
26) Palumbo A, Bringhen S, Mateos MV et al : Geriatric assessment predicts survival and toxicities in elderly myeloma patients : an International Myeloma Working Group report. Blood 125 : 2068-2074, 2015
27) Palumbo A, Bringhen S, Ludwig H et al : Personalized therapy in multiple myeloma according to patient age and vulnerability : a report of the European Myeloma Network (EMN). Blood 118 : 4519-4529, 2011
28) Durie BG, Harousseau JL, Miguel JS et al : International uniform response criteria for multiple myeloma. Leukemia 20 : 1467-1473, 2006
29) Kumar S, Paiva B, Anderson KC et al : International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17 : e328-e346, 2016
30) Rajkumar SV, Harousseau JL, Durie B et al : Consensus recommendations for the uniform reporting of clinical trials : report of the International Myelorna Workshop Consensus Panel 1. Blood 117 : 4691-4695, 2011
31) Barlogie B, Mitchell A, van Rhee F et al : Curing myeloma at last : defining criteria and providing the evidence. Blood 124 : 3043-3051, 2014
32) Terpos E, Dimopoulos MA, Moulopoulos LA : The role of imaging in the treatment of patients with multiple myeloma in 2016. Am Soc Clin Oncol Educ Book 35 : e407-e417, 2016
P.23 掲載の参考文献
1) Manier S, Salem KZ, Park J et al : Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol 14 : 100-113, 2017
2) Bolli N, Avet-Loiseau H, Wedge DC et al : Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nature Communications 5 : 2997, 2014
3) Morgan GJ, Walker BA, Davies FE : The genetic architecture of multiple myeloma. Nat Rev Cancer 12 : 335-348, 2012
4) Chesi M, Bergsagel PL : Molecular pathogenesis of multiple myeloma : basic and clinical updates. Int J Hematol 97 : 313-323, 2013
5) Palumbo A, Anderson K : Multiple myeloma. N Engl J Med 364 : 1046-1060, 2011
6) Mimura N, Hideshima T, Anderson KC : Novel therapeutic strategies for multiple myeloma. Exp Hematol 43 : 732-741, 2015
7) Hideshima T, Mitsiades C, Tonon G et al : Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7 : 585-598, 2007
8) Lucia DM, Vanessa D, Antonio GS et al : Microenvironment drug resistance in multiple myeloma : emerging new players. Oncotarget 7 : 60698-60711, 2016
9) Lee SJ, Borrello I : Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma. Plasma Cell Dyscrasias. Vol 169. Cancer Treatment and Research. Cham : Springer International Publishing, 2016, pp. 207-225
10) Prabhala RH, Pelluru D, Fulciniti M et al : Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 115 : 5385-5392, 2010
11) Bryant C, Suen H, Brown R et al : Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J 3 : e148-e147, 2013
12) Prabhala RH, Neri P, Bae JE et al : Dysfunctional T regulatory cells in multiple myeloma. Blood 107 : 301-304, 2006
13) Muthu Raja KR, Rihova L, Zahradova L et al : Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS ONE 7 : e47077, 2012
14) Gupta R, Ganeshan P, Hakim M et al : Significantly reduced regulatory T cell population in patients with untreated multiple myeloma. Leuk Res 35 : 874-878, 2011
15) Favaloro J, Liyadipitiya T, Brown R et al : Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. Leuk Lymphoma 55 : 2893-2900, 2014
16) Ramachandran IR, Martner A, Pisklakova A et al : Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol 190 : 3815-3823, 2013
17) Kawano Y, Moschetta M, Manier S et al : Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev 263 : 160-172, 2015
18) Rebmann V, Schutt P, Brandhorst D et al : Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. Clin Immunol 123 : 114-120, 2007
19) Hideshima T, Richardson P, Chauhan D et al : The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61 : 3071-3076, 2001
20) Adams J : The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5 : 417-421, 2004
21) Rajkumar SV, Witzig TE : A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treatment Reviews 26 : 351-362, 2000
22) Zhu YX, Braggio E, Shi C-X et al : Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118 : 4771-4779, 2011
23) Steinbrunn T, Stuhmer T, Sayehli C et al : Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma. Br J Haematol 159 : 430-440, 2012
24) Shimura Y, Kuroda J, Ri M et al : RSK2 (Ser 227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma. Mol Cancer Ther 11 : 2600-2609, 2012
25) Chinen Y, Kuroda J, Shimura Y et al : Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma. Cancer Res 74 : 7418-7429, 2014
26) Hiasa M, Teramachi J, Oda A et al : Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma. Leukemia 29 : 207-217, 2015
27) Touzeau C, Dousset C, Le Gouill S et al : The Bcl-2 specific BH3 mimetic ABT-199 : a promising targeted therapy for t (11 ; 14) multiple myeloma. Leukerma 28 : 210-212, 2014
28) Lonial S, Dimopoulos M, Palumbo A et al : Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373 : 621-631, 2015
29) Palumbo A, Chanan-Khan A, Weisel K et al : Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med 375 : 754-766, 2016
30) Hoyos V, Borrello I : The immunotherapy era of myeloma : monoclonal antibodies, vaccines, and adoptive T-cell therapies. Blood 128 : 1679-1687, 2016
31) Atanackovic D, Radhakrishnan SV, Bhardwaj Netal : Chimeric Antigen Receptor (CAR) therapy for multiple myeloma. Br J Haematol 172 : 685-698, 2016

Chapter 2 各種治療薬の使い方・考え方

P.33 掲載の参考文献
1) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma : an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists'Collaborative Group. J Clin Oncol 16 : 3832-3842, 1998
2) Singhal S, Mehta J, Desikan R et al : Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341 : 1565-1571, 1999
4) Kumar SK, Dispenzieri A, Lacy MQ et al : Continued improvement in survival in multiple myeloma : changes in early mortality and outcomes in older patients. Leukemia 28 : 1122-1128, 2014
5) Saeki Y : Ubiquitin recognition by the proteasome. J Biochem 161 : 113-124, 2017
6) Hideshima T, Mitsiades C, Akiyama M et al : Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101 : 1530-1534, 2003
7) Demo SD, Kirk CJ, Aujay MA et al : Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67 : 6383-6391, 2007
8) Hideshima T, Chauhan D, Richardson P et al : NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 277 : 16639-16647, 2002
9) Obeng EA, Carlson LM, Gutman DM et al : Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107 : 4907-4916, 2006
10) Richardson PG, Barlogie B, Berenson J et al : A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 : 2609-2617, 2003
11) Richardson PG, Sonneveld P, Schuster MW et al : Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 : 2487-2498, 2005
12) San Miguel JF, Schlag R, Khuageva NK et al : Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359 : 906-917, 2008
13) Mateos MV, Richardson PG, Schlag R et al : Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma : updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 28 : 2259-2266, 2010
14) Harousseau JL, Attal M, Avet-Loiseau H et al : Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma : results of the IFM 2005-01 phase III trial. J Clin Oncol 28 : 4621-4629, 2010
15) Cavo M, Pantani L, Petrucci MT et al : Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Btood 120 : 9-19, 2012
16) Sonneveld P, Goldschmidt H, Rosinol L et al : Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma : a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 31 : 3279-3287, 2013
17) Durie BG, Hoering A, Abidi MH et al : Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777) : a randomised, open-label, phase 3 trial. Lancet 389 : 519-527, 2016
18) Stewart AK, Rajkumar SV, Dimopoulos MA et al : Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372 : 142-152, 2015
19) Dimopoulos MA, Moreau P, Palumbo A et al : Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR) : a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17 : 27-38, 2016
20) Moreau P, Masszi T, Grzasko N et al : Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 374 : 1621-1634, 2016
21) Davies F, Baz R : Lenalidomide mode of action : linking bench and clinical findings. Blood Rev 24 Suppl 1 : S13-S19, 2010
22) Palumbo A, Bringhen S, Caravita T et al : Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma : randomised controlled trial. Lancet 367 : 825-831, 2006
23) Facon T, Mary JY, Hulin C et al : Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06) : a randomised trial. Lancet 370 : 1209-1218, 2007
24) Morgan GJ, Gregory WM, Davies FE et al : The role of maintenance thalidomide therapy in multiple myeloma : MRC Myeloma IX results and meta-analysis. Blood 119 : 7-15, 2012
25) Dimopoulos MA, Sonneveld P, Leung N et al : International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol 34 : 1544-1557, 2016
26) Dimopoulos M, Spencer A, Attal M et al : Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357 : 2123-2132, 2007
27) Dimopoulos MA, Chen C, Spencer A et al : Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23 : 2147-2152, 2009
28) Benboubker L, Dimopoulos MA, Dispenzieri A et al : Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 371 : 906-917, 2014
29) San Miguel J, Weisel K, Moreau P et al : Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003) : a randomised, open-label, phase 3 trial. Lancet Oncol 14 : 1055-1066, 2013
30) Dimopoulos MA, Weisel KC, Song KW et al : Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica 100 : 1327-1333, 2015
31) Weisel KC, Dimopoulos MA, Moreau P et al : Analysis of renal impairment in MM-003, a phase III study of pomalidomide+low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica 101 : 872-878, 2016
32) Li Y, Seto E : HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med 6 : a026831, 2016
33) Hideshima T, Bradner JE, Wong J et al : Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 102 : 8567-8572, 2005
34) Vogl DT, Raje NS, Jagannath S et al : Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Clin Cancer Res 2017 [Epub ahead of print]
35) Richardson PG, Schlossman RL, Alsina M et al : PANORAMA 2 : panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 122 : 2331-2337, 2013
36) San-Miguel JF, Hungria VT, Yoon SS et al : Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial) : a randomised, placebo-controlled, phase 3 trial. Lancet Haematol 3 : e506-e515, 2016
37) Afifi S, Michael A, Lesokhin A : Immunotherapy : A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab. Ann Pharmacother 50 : 555-568, 2016
38) Collins SM, Bakan CE, Swartzel GD et al : Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation : evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother 62 : 1841-1849, 2013
39) Lonial S, Dimopoulos M, Palumbo A et al : Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med 373 : 621-631, 2015
40) Palumbo A, Chanan-Khan A, Weisel K et al : Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med 375 : 754-766, 2016
41) Dimopoulos MA, Oriol A, Nahi H et al : Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 375 : 1319-1331, 2016
42) Dizon MF : The Challenges of Daratumumab in Transfusion Medicine. Lab Med 48 : 6-9, 2016
P.51 掲載の参考文献
1) ベルケイド(R) 医薬品インタビューフォーム 第10版, ヤンセンファーマ株式会社
2) Reeder CB, Reece DE, Kukreti V et al : Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 115 : 3416-3417, 2010
3) Yagi H, Fujii A, Minamoto S, Fujita M et al : Once-weekly Bortezomib in Combination with Reduced-dose Dexamethasone and Continuous Low-dose Oral Cyclophosphamide for Elderly Patients with Multiple Myeloma. J Hematol Thrombo Dis 5 : 261, 2017
4) San Miguel JF, Schlag R, Khuagera NK et al : VISTA Trial Investivators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359 : 906-917, 2008
5) Cavo M, Pantani L, Petrucci MT : Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 120 : 9-19, 2012
6) San Miguel JF, Schlag R, Khuagera NK et al : Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 31 : 448-455, 2013
7) Moreau P, Avet-Loiseau H, Facon T et al : Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118 : 5752-5758, 2011
8) Roussel M, Lauwers-Cances V, Robillard N et al : Front-Line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma : a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol 32 : 2712-2717, 2014
P.65 掲載の参考文献
1) カイプロリス(R) 点滴静注用 医薬品インタビューフォーム (初版), 小野薬品工業株式会社
2) Stewart AK, Rajkumar SV, Dimopoulos MA et al : Carfilzomib, lenalidomide, and dexamethasone forrelapsed multiple myeloma. N Engl J Med 372 : 142-152, 2015
3) Dimopoulos MA, Moreau P, Palumbo A et al : Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR) : a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17 : 27-38, 2016
4) Niesvizky R, Martin TG 3rd, Bensinger WI et al : Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res 19 : 2248-2256, 2013
5) Wang M, Martin T, Bensinger W et al : Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 122 : 3122-3128, 2013
6) Avet-Loiseau H, Fonseca R, Siegel D et al : Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood 128 : 1174-1180, 2016
7) Suzuki K, Ri M, Chou T et al : Carfilzomib, lenalidomide, and dexamethasone in patients with heavily-pretreated multiple myeloma : A phase 1 study in Japan. Cancer Sci 108 : 461-468, 2017
P.78 掲載の参考文献
1) Moreau P, Masszi T, Grzasko N et al : Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374 : 1621-1634, 2016
2) Kumar SK, Berdoja, JG, Niesvizky R et al : Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma : an open-label phase 1/2 study. Lancet Oncol 15 : 1503-1512, 2014
3) Chauhan D, Tian Z, Zhou B et al : In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 17 : 5311-5321, 2011
4) Kupperman E, Lee EC, Cao Y et al : Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 70 : 1970-1980, 2010
5) Kumar SK, Bensinger WI, Zimmerman TM et al : Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood 124 : 1047-1055, 2014
6) Richardson PG, Baz R, Wang M et al : Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma. Blood 124 : 1038-1046, 2014
7) Garcia-Gomez A, Quwaider D, Canavese M et al : Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease. Clin Cancer Res 20 : 1542-1554, 2014
8) ニンラーロ(R) 適正使用ガイド, 武田薬品工業株式会社
9) Kumar S, Moreau P, Hari P et al : Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. Br J Haematol, 2017 [Epub ahead of print]
10) Maria VM, Tamas M, Norbert G et al : Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1. [abstract]. J Clin Oncol 34 : Abstract 8039, 2016
11) Avet-Loiseau H, Bahlis NJ, Chng WJ et al : Impact of cytogenetic risk status on efficacy and safety of ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in relapsed/refractory multiple myeloma patients in the global TOURMALINE-MM1 study [abstract]. Hematologica 101 : 80, 2016
12) Suzuki K, Handa H, Chou T et al : Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma. Int J Hematol 105 : 445-452, 2017
13) Gupta N, Zhao Y, Hui AM et al : Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib : a population pharmacokinetic analysis. Br J Clin Pharmacol 79 : 789-800, 2015
14) Richardson PG, Xie W, Jagannath S et al : A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood 123 : 1461-1469, 2014
15) Steward AK, Rajkumar SV, Dimopoulos MA et al : Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372 : 142-152, 2014
16) Moreau P, Hulin C, Caillot D et al : Ixazomib-lenalidomide-dexamethasone (IRd) combination before and after autologous stem cell transplantation (ASCT) followed by ixazomib maintenance in patients with newly diagnosed multiple myeloma (NDMM) : a phase 2 study from Intergroupe Francophone Du MyeLome (IFM) [abstract]. Blood 128 : 674, 2016
P.90 掲載の参考文献
1) サレド(R) カプセル添付文書, 藤本製薬株式会社
2) サレド(R) カプセル適正使用ガイド, 藤本製薬株式会社
3) Fink EC, Ebert BL : The novel mechanism of lenalidomide activity. Blood 126 : 2366-2369, 2015
4) Nowakowski GS : Evolution : IMiDs to PPMs, revolution in DLBCL? Blood 126 : 698-700, 2015
5) Stewart AK : Medicine. How thalidomide works against cancer. Science 343 : 256-257, 2014
6) Fischer ES, Bohm K, Lydeard JR et al : Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512 : 49-53, 2014
7) Facon T, Mary JY, Hulin C et al : Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06) : a randomised trial. Lancet 370 : 1209-1218, 2007
8) Benboubker L, Dimopoulos MA, Dispenzieri A et al : Lenalidomide and dexamethasone in transplantineligible patients with myeloma. N Engl J Med 371 : 906-917, 2014
9) Moreau P, Avet-Loiseau H, Facon T et al : Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118 : 5752-5758, 2011
10) NCCN Clinical Practice Guidelines in Oncology Multiple Myeloma, Ver 3, 2017
11) Palumbo A, Bringhen S, Caravita T et al : Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma : randomised controlled trial. Lancet 367 : 825-831, 2006
12) Palumbo A, Bringhen S, Liberati AM et al : Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma : updated results of a randomized controlled trial. Blood 112 : 3107-3114, 2008
13) Hulin C, Facon T, Rodon P et al : Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma : IFM 01/01 trial. J Clin Oncol 27 : 3664-3670, 2009
14) Wijermans P, Schaafsma M, Termorshuizen F et al : Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma : the HOVON 49 Study. J Clin Oncol 28 : 3160-3166, 2010
15) Waage A, Gimsing P, Fayers P et al : Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116 : 1405-1415, 2010
16) Zangari M, Aujay M, Zhan F et al : Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol 86 : 484-487, 2011
17) Fayers PM, Palumbo A, Hulin C et al : Thalidomide for previously untreated elderly patients with multiple myeloma : meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118 : 1239-1247, 2011
18) サレド(R) インタビューフォーム, 藤本製薬株式会社
19) Palumbo A, Gay F : How to treat elderly patients with multiple myeloma : combination of therapy or sequencing. Hematology Am Soc Hematol Educ Program, 566-577, 2009
20) Palumbo A, Anderson K : Multiple myeloma. N Engl J Med 364 : 1046-1060, 2011
21) Weisel K, Doyen C, Dimopoulos M et al : A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation. Leuk Lymphoma 58 : 153-161, 2017
22) Stewart AK, Jacobus S, Fonseca R et al : Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood 126 : 1294-1301, 2015
23) Zweegman S, van der Holt B, Mellqvist UH et al : Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood 127 : 1109-1116, 2016
P.110 掲載の参考文献
1) Quach H, Ritchie D, Stewart AK et al : Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 24 : 22-32, 2010
2) Rajkumar SV, Jacobus S, Callander NS et al : Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma : an open-label randomised controlled trial. Lancet Oncol 11 : 29-37, 2010
3) Palumbo A, Hajek R, Delforge M et al : Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366 : 1759-1769, 2012
4) Durie BG, Hoering A, Abidi MH, et al : Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777) : a randomised. open-label, phase 3 trial. Lancet 389 : 519-527, 2017
5) Palumbo A, Cavallo F, Gay F et al : Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371 : 895-905, 2014
6) Benboubker L, Dimopoulos MA, Dispenzieri A et al : Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 371 : 906-917, 2014
7) Stewart AK, Rajkumar SV, Dimopoulos MA et al : Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372 : 142-152, 2014
8) Lonial S, Dimopoulos M, Palumbo A et al : Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med 373 : 621-631, 2015
P.122 掲載の参考文献
1) Richardson PG, Siegel DS, Vij R et al : Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma : a randomized phase 2 study. Blood 123 : 1826-1832, 2014
2) San Miguel J, Weisel K, Moreau P et al : Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003) : a randomized, open-label, phase 3 trial. Lancet Oncol 14 : 1055-1066, 2013
3) Richardson PG, Hofmeister CC, Siegel DS et al : MM-005 : a phase 1 trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM). ASH Annual Meeting 2013 : Abstract 1969.
4) ポマリスト(R) 医薬品インタビューフォーム, セルジーン株式会社
5) Bjorklund CC, Lu L, Kang J et al : Rate of CRL4CRBN substrate Ikaros and Aiolos degradeation underlies differential activety of lenalidomide and pomalidomide in multiple myeloma cells by regulateon of c-Myc and IRF4. Blood Cancer J 5 : e354, 2015
6) Weisel K, Dimopoulos M, van de Donk N et al : Safety results of a phase 2, multicenter, open-label study of pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and renal impairment ASH Annual Meeting 2016 : Abstract 3311.
7) Chari A, Cho HJ, Parekh S et al : A Phase II study of pomalidomide, daily low dose oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. ASH Annual Meeting 2016, abstract 4520
8) Ichinohe T, Kuroda Y, Okamoto S et al : A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma : the Japanese MM-011 trial. Exp Hematol Oncol 5 : 11, 2016
9) Siegel DS, Schiller GJ, Song KW et al : Pomalidomide+low-dose dexamethasone following second-line lenalidomide-based therapy in relapsed or refractory multiple myeloma : a phase 2 study investing efficacy and safety. ASH Annual Meeting 2016 : Abstract 4497.
10) Wang M, Martin T, Bensinger W et al : Phase 2 dose-exapansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 122 : 3122-3128, 2013
11) Ito S, Oyake T, Murai K et al : Successful use of cyclophosphamide as an add-on therapy for multiple myeloma patients with acquired resistance to bortezomib or lenalidomide. Case Rep Hematol 2013, 651902, 2013
12) Ghosh N, Tucker N, Zahurak M et al : Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma. Am J Hematol 89 : E116-E120, 2014
P.133 掲載の参考文献
1) Hideshima T, Richardson PG, Anderson KC : Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther 10 : 2034-2042, 2011
2) HDAC阻害剤 ファリーダックの作用機序, ノバルティスファーマ株式会社, 2016
3) San-Miguel JF, Hungria VT, Yoon SS et al : Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma : a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 15 : 1195-1206, 2014
4) San-Miguel JF, Hungria VT, Yoon SS et al : Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial) : a randomised, placebo-controlled, phase 3 trial. Lancet Haematol 3 : e506-e515, 2016
5) Richardson PG, Schlossman RL, Alsina M et al : PANORAMA 2 : panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezornib refractory myeloma. Blood 122 : 2331--2337, 2013
P.149 掲載の参考文献
1) Zonder JA, Mohrbacher AF, Singhal S et al : A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 120 : 552-559, 2012
2) Lonial S, Dimopoulos M, Palumbo A et al : Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med 373 : 621-631, 2015
3) NCCN Guideline Multiple myeloma, Version 3, 2017
4) Hsi ED, Steinle R, Balasa B et al : CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 14 : 2775-2784, 2008
5) Collins SM, Bakan CE, Swartzel GD et al : Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation : evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother 62 : 1841-1849, 2013
6) Liu YC, Szmania S, van Rhee F et al : Profile of elotuzumab and its potential in the treatment of multiple myeloma. Blood Lymphat Cancer 2014 : 15-27, 2014
7) エムプリシティ(R) 適正使用ガイド, ブリストル・マイヤーズスクイブ株式会社
8) Ohashi K, Suzuki K, Sunami K et al : Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial. ASH 2016 Annual Meeting, Abstract 3315
9) Jakubowiak A, Offidani M, Pegourie B et al : Randomized phase 2 study : elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood 127 : 2833-2840, 2016
P.158 掲載の参考文献
1) https://www.janssenmd.com/pdf/darzalex/DARZALEX_PI.pdf
2) Laubach JP, Tai YT, Richardson PG et al : Daratumumab granted breakthrough drug status. Expert Opin Investig Drugs 23 : 445-452, 2014
3) Lonial S, Weiss BM, Usmani SZ et al : Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS) : an open-label, randomised, phase 2 trial. Lancet 387 : 1551-1560, 2016
4) Palumbo A, Chanan-Khan A, Weisel K et al : Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med 375 : 754-766, 2016
5) Dimopoulos MA, Oriol A, Nahi H et al : Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 375 : 1319-1331, 2016

Chapter 3 期待される次世代の治療

P.165 掲載の参考文献
1) Topalian SL, Hodi FS, Brahmer JR et al : Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 : 2443-2454, 2012
2) Brahmer JR, Tykodi SS, Chow LQ et al : Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 : 2455-2465, 2012
3) Younes A, Santoro A, Shipp M et al : Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin : a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17 : 1283-1294, 2016
4) Ishida Y, Agata Y, Shibahara K et al : Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1 1 : 3887-3895, 1992
5) Shinohara T, Taniwaki M, Ishida Y et al : Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics 23 : 704-706, 1994
6) Nishimura H, Okazaki T, Tanaka Y et al : Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291 : 319-322, 2001
7) Dong H, Zhu G, Tamada K et al : B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5 : 1365-1369, 1999
8) Tamura H, Dong H, Zhu G et al : B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood 97 : 1809-1816, 2001
9) Freeman GJ, Long AJ, Iwai Y et al : Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192 : 1027-1034, 2000
10) Dong H, Strome SE, Salomao DR et al : Tumor-associated B7-H1 promotes T-cell apoptosis : a potential mechanism of immune evasion. Nat Med 8 : 793-800, 2002
11) Hirano F, Kaneko K, Tamura H et al : Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65 : 1089-1096, 2005
12) Kiyasu J, Miyoshi H, Hirata A et al : Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 126 : 2193-2201, 2015
13) Tamura H, Ishibashi M, Yamashita T et al : Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 27 : 464-472, 2013
14) Liu J, Hamrouni A, Wolowiec D et al : Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110 : 296-304, 2007
15) Lee SJ, Jang BC, Lee SW et al : Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274). FEBS Lett 580 : 755-762, 2006
16) An G, Acharya C, Feng X et al : Osteoclast promote immune suppressive microenvironment in multiple myeloma : therapeutic implication. Blood 128 : 1590-1603, 2016
17) Paiva B, Azpilikueta A, Puig N et al : PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia 29 : 2110-2113, 2015
18) Ishibashi M, Tamura H, Sunakawa M et al : Interaction between B7-H1 (PD-L1) on myeloma cells and PD-1 induces myeloma cell drug resistance. Cancer Immunol Res 4 : 779-788, 2016
19) Dhodapkar MV, Sexton R, Das R, et al : Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. Blood 126 : 2475-2478, 2015
20) Sponaas AM, Moharrami NN, Feyzi E et al : PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy. PLoS One 10 : e0139867, 2015
21) Frigola X, Inman BA, Lohse CM et al : Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma. Clin Cancer Res 17 : 1915-1923, 2011
22) Sunakawa M, Ishibashi M, Moriya K et al : Clinical impact of soluble B7-H1 (PD-L1) in multiple myeloma. International Myeloma Workshop 2017, abstract.
23) Wang L, Wang H, Chen H et al : Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget 6 : 41228-41236, 2015
24) Lesokhin AM, Ansell SM, Armand P et al : Nivolumab in patients with relapsed or refractory hematologic malignancy : preliminary results of phase Ib study. J Clin Oncol 34 : 2698-2704, 2016
25) Suen H, Brown R, Yang S et al : The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study. Leukemia 29 : 1621-1622, 2015
26) Benson DM Jr, Bakan CE, Mishra A et al : The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect : a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116 : 2286-2294, 2010
27) Gorgun G, Samur MK, Cowens KB et al : Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res 21 : 4607-4618, 2015
28) Mateos MV, Orlowski RZ, Siegel DS et al : Pembrolizumab in combination with lenalidomide and low dose dexamethasone for relapsed/refractory multiple myeloma (RRMM) : Final Efficacy and safety analysis. J Clin Oncol 34 (suppl ; abstract 8010), 2016
29) Shah JJ, Jagannath S, Mateos MV et al : Keynote-183 : A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory mutliple myeloma. J Clin Oncol 34 ASCO Annual Meeting (suppl ; abstract TPS8070), 2016
30) Palumbo A, Mateos MV, San Miguel et al : Keynote-185 : A randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma. J Clin Oncol ASCO Annual Meeting ; 34 (suppl ; abstract TPS8069), 2016
P.172 掲載の参考文献
1) Porter DL, Levine BL, Kalos M et al : Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365 : 725-733, 2011
2) Maude SL, Frey N, Shaw PA et al : Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. New Eng J Med 371 : 1507-1517, 2014
3) Kalos M, Levine BL, Porter DL et al : T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3 : 95ra73, 2011
4) Brentjens RJ, Davila ML, Riviere I et al : CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5 : 177ra38-177ra38, 2013
5) Kochenderfer JN, Dudley ME, Kassim SH et al : Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor. J Clin Oncol 33 : 540-549, 2015
6) Lee DW, Kochenderfer JN, Stetler-Stevenson M et al : T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults : a phase 1 dose-escalation trial. Lancet 385 : 517-528, 2015
7) Garfall AL, Maus MV, Hwang WT et al : Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med 373 : 1040-1047, 2015
8) Ali SA, Shi V, Maric I et al : T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128 : 1688-1700, 2016
9) Cohen MD, Garfall AL, Stadtmauer EA et al : B-Cell Maturation Antigen (BCMA) -Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM) : Initial Safety and Efficacy from a Phase I Study. ASH2016, session 653, 1147
10) Garfall AL, Stadtmauer EA, Maus MV et al : Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. ASH2016, session 653, 974
11) Ramos CA, Savoldo B, Torrano V et al : Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J Clin Invest 126 : 2588-2596, 2016
12) Brown CE, Alizadeh D, Starr R et al : Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med 375 : 2561-2569, 2016
P.178 掲載の参考文献
1) Souers AJ, Leverson JD, Boghaert ER et al : ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19 : 202-208, 2013
2) Green DR, Walczak H : Apoptpsis therapy : driving cancers down the road to ruin. Nat Med 19 : 131-133, 2013
3) Kumar S, Vij R, Kaufman JL et al : Venetoclax monotherapy for relapsed/refractory multiple myeloma : saferty and efficacy results from a phase I study. Blood 128 : 58th annual meeting abst 488, 2016
4) Moreau P, Chanan-Khan AA, Roberts AW et al : Venetoclax combined with bortezomib and dexamethasone for patients with relapsed/refractory multiple myeloma. Blood 128 : 58th annual meeting abst 975, 2016
5) Tai YT, Landesman Y, Acharya C et al : CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma : molecular mechanisms and therapeutic implications. Leukemia 28 : 155-165, 2014
6) Vogt DT, Dingli D, Cornell RF et al : Selinexor and low dose dexamethasone (Sd) in patients with lenalidomide, pomalidomide, bortezomib, carfilzomib, and anti-CD38 Ab refractory multiple myeloma : STORM study. Blood 128 : 58th annual meeting abst 491, 2016
7) Bahlis NJ, Kotb R, Sebag M et al : Selinexor in combination with bortezomib & dexamethasone (SdB) demonstrates significant activity in patients with refractory multiple myeloma including proteasome-inhibitor refractory patients : results of the phase I Stomp trial. Blood 128 : 58th annual meeting abst 977, 2016
8) Driessen C, Kraus M, Joerger M et al : Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib : a phase I trial (SAKK 65/08). Haematologica 101 : 346-355, 2016
9) Driessen C, Muller R, Novak U et al : The HIV protease inhibitor Nelfinavir in combination with bortezomib and dexamethasone (NVd) has excellent activity in patients with advanced proteasome inhibitor--refractory multiple myeloma : a multicenter phase II trial (SAKK 39/13). Blood 128 : 58th annual meeting abst 487, 2016

最近チェックした商品履歴

Loading...